Supportive care+Prednisone
TAC and ripertamab in MCD
Phase 3 small_molecule active
Quick answer
Supportive care+Prednisone for Minimal Change Disease is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Minimal Change Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active